Neuland Laboratories Ltd. (IN:NEULANDLAB)
:NEULANDLAB
Want to see IN:NEULANDLAB full AI Analyst Report?
Top Page
Neuland Laboratories Ltd.
(NEULANDLAB)
Select Model
Select Model
Rating:69Neutral
Price Target:
₹18,017.00
▲(18.02% Upside)
Action:Downgraded
Date:05/14/26
The score is driven primarily by solid profitability and a conservatively leveraged balance sheet, supported by strong technical uptrend and momentum. Offsetting these positives are weaker cash-flow quality (negative FY2026 free cash flow) and a demanding valuation (high P/E with very low dividend yield).
Positive Factors
Profitability & margins
Consistent mid-to-high teens net margins and robust EBIT margins signal durable core profitability. This margin base supports reinvestment in process R&D and scale-up, provides a cushion against industry cyclicality, and underpins sustainable earnings over the coming months.
Negative Factors
Weaker cash-flow conversion
Despite positive reported profits, conversion to cash is only moderate and free cash flow fell negative in FY2026. This reduces internal funding for capex, working capital or dividends, increases reliance on financing, and raises vulnerability to margin or demand shocks over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability & margins
Consistent mid-to-high teens net margins and robust EBIT margins signal durable core profitability. This margin base supports reinvestment in process R&D and scale-up, provides a cushion against industry cyclicality, and underpins sustainable earnings over the coming months.
Read all positive factors
Neuland Laboratories Ltd. (NEULANDLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹213.32B
Dividend Yield0.08%
Average Volume (3M)2.41K
Price to Earnings (P/E)42.4
Beta (1Y)1.32
Revenue Growth36.98%
EPS Growth39.94%
CountryIN
Employees1,643
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)187.17
Shares Outstanding12,829,889
10 Day Avg. Volume1,318
30 Day Avg. Volume2,408
Financial Highlights & Ratios
PEG Ratio1.06
Price to Book (P/B)8.23
Price to Sales (P/S)7.63
P/FCF Ratio-262.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)338.23
Revenue Forecast (FY)₹22.42B
Neuland Laboratories Ltd. Business Overview & Revenue Model
Company Description
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovascul...
How the Company Makes Money
Neuland Laboratories makes money primarily by manufacturing and selling active pharmaceutical ingredients (APIs) and by providing contract development and manufacturing services to pharmaceutical companies.
Key revenue streams include:
1) API sal...
Neuland Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
78
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.91B | 20.23B | 14.34B | 15.16B | 11.61B | 9.23B |
| Gross Profit | 7.31B | 6.43B | 6.84B | 7.82B | 5.47B | 3.70B |
| EBITDA | 4.02B | 5.74B | 4.18B | 4.72B | 2.79B | 1.41B |
| Net Income | 2.40B | 3.64B | 2.60B | 3.00B | 1.64B | 638.22M |
Balance Sheet | ||||||
| Total Assets | 25.34B | 29.30B | 21.80B | 18.33B | 15.80B | 13.83B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 3.55B | 3.67B | 1.03B | 454.16M | 84.68M |
| Total Debt | 2.65B | 3.01B | 1.57B | 953.90M | 1.28B | 2.41B |
| Total Liabilities | 9.14B | 10.56B | 6.55B | 5.50B | 5.86B | 5.43B |
| Stockholders Equity | 16.20B | 18.74B | 15.25B | 12.83B | 9.94B | 8.41B |
Cash Flow | ||||||
| Free Cash Flow | -2.07B | -588.87M | 1.11B | 1.18B | 1.71B | -372.97M |
| Operating Cash Flow | -367.47M | 3.38B | 3.17B | 2.61B | 2.37B | 603.89M |
| Investing Cash Flow | -521.95M | -4.32B | -2.98B | -1.50B | -614.99M | -955.16M |
| Financing Cash Flow | -19.30M | 380.18M | 249.61M | -692.82M | -1.36B | 377.21M |
Neuland Laboratories Ltd. Technical Analysis
Positive
15265.60
Price Trends
14247.30
Positive
14099.07
Positive
14733.13
Positive
Market Momentum
721.85
Positive
61.68
Neutral
23.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NEULANDLAB, the sentiment is Positive. The current price of 15265.6 is below the 20-day moving average (MA) of 15995.08, above the 50-day MA of 14247.30, and above the 200-day MA of 14733.13, indicating a bullish trend. The MACD of 721.85 indicates Positive momentum. The RSI at 61.68 is Neutral, neither overbought nor oversold. The STOCH value of 23.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NEULANDLAB.
Neuland Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹1.83T | 72.71 | ― | 0.46% | 13.62% | 19.93% | |
74 Outperform | ₹130.03B | 21.18 | ― | 0.56% | 6.91% | 16.04% | |
74 Outperform | ₹881.60B | 18.87 | ― | 0.33% | 7.31% | 0.34% | |
69 Neutral | ₹213.32B | 42.39 | ― | 0.08% | 36.98% | 39.94% | |
66 Neutral | ₹187.93B | 18.85 | ― | 0.24% | 19.73% | 18.17% | |
59 Neutral | ₹734.91B | 48.00 | ― | 0.15% | 22.67% | 147.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:NEULANDLAB
Neuland Laboratories Ltd.
16,626.50
5,448.91
48.75%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,517.90
318.45
26.55%
IN:DIVISLAB
Divi's Laboratories Limited
6,893.20
371.99
5.70%
IN:ALIVUS
Glenmark Life Sciences Limited
1,059.40
-35.37
-3.23%
IN:GRANULES
Granules India Limited
758.40
242.53
47.01%
IN:LAURUSLABS
Laurus Labs Ltd.
1,361.30
765.34
128.42%
Neuland Laboratories Ltd. Corporate Events
Neuland Laboratories Posts Audio Recording of FY 2026 Earnings Call Online
May 12, 2026
Neuland Laboratories Ltd. has notified the stock exchanges that the audio recording of its earnings call for the quarter and year ended March 31, 2026, held on May 12, 2026, is now available online. The company has provided a dedicated weblink on ...
Neuland Laboratories Reports Loss of Share Certificate by Investor
Mar 12, 2026
Neuland Laboratories Ltd. has informed the stock exchanges that a shareholder, identified under folio number 0005239, has reported the loss of a physical share certificate representing 100 shares. The company has received a request from this share...
Neuland Labs Schedules Non-Deal Roadshows in Hong Kong and Singapore
Mar 3, 2026
Neuland Laboratories has announced a schedule of upcoming interactions with analysts and institutional investors as part of non-deal roadshows organized by BK Securities. These meetings will include both group and one-on-one sessions in Hong Kong ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.